Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.
Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia
Rather than unpacking the actual causes of Lykos Therapeutics' disastrous Phase 3 trials and FDA rejection, The New York Times produced a work of fictitious propaganda that prioritizes corporate interests over public health.
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Power Tripping offers an inside look at Psymposia and New York Magazine’s podcast “Cover Story: Power Trip.” Join the co-creators and the rest of the Psymposia team for deep dives into the histories, characters, and events that shaped our investigation.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Listen on Spotify, Apple Podcasts, or wherever podcasts are available.
Cover Story is an investigative podcast from New York Magazine. The first season, Power Trip, uncovers the secrets and exposes the darkest corners of the psychedelic renaissance through a twisted, deeply personal tale at the intersection of mind, body, and control. Power Trip is a co-production of New York Magazine and Psymposia.
Featured Stories
Correcting the Record: What The New York Times Got Wrong
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.
Featured Stories
Correcting the Record: What The New York Times Got Wrong
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.
Psymposia’s Response to Heroic Hearts’ Pharma-Backed Press Conference
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.
Every Disclosed Conflict of Interest at Psychedelic Science 2023
All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.
Psychedelic Science 2023 Contract Muzzles Speakers: Two Clauses Dictate What Presenters Can and Can’t Say
In order to present at Psychedelic Science 2023, speakers must agree to two out-of-the-ordinary requests about content exclusivity and MAPS’ reputation.
Psymposia is a 501(c)(3) non-profit media organization that offers critical perspectives on drugs, politics, and culture. We are sustained by our readers and listeners who believe in the work we do. If you support our work please become a monthly donor on Patreon or make a one-time donation.
Psymposia, Inc. TAX ID: 85-0630940. Your donation is tax-deductible to the full extent allowed by law. For questions about donations, or to donate by check, wire, digital currency, or other means, please send us an email. To donate using PayPal click here.
Featured Stories
Psymposia’s Response to Heroic Hearts’ Pharma-Backed Press Conference
Veterans deserve the highest quality treatment for PTSD. It’s unacceptable and dangerous to use veterans as guinea pigs for a big pharma profit grab without resolving safety and efficacy concerns.
Correcting the Record: What The New York Times Got Wrong
In response to the The New York Times February 4 article, "How a Leftist Activist Group Helped Torpedo a Psychedelic Therapy," Psymposia requested corrections to numerous errors and false accusations.
Every Disclosed Conflict of Interest at Psychedelic Science 2023
All the financial conflict disclosures from Psychedelics Science 2023 speakers, in one handy list.
#48 – Drugs and Anti-Capitalism with Hilary Agro
We talk drugs and anti-capitalism with anthropology PhD candidate, Hilary Agro. Ranging from prohibition to psychedelic clinical trials and beyond, we explore the overlaps and differences in our analyses of the current psychedelic (and broader drug policy) landscape.
#47 – Part Two: Right Wing Psychedelia
We continue our discussion about Brian Pace and Neşe Devenot's recently published paper: "Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency"
#46 – Part One: Right Wing Psychedelia
We discuss Brian Pace and Neşe Devenot's recently published paper: "Right-Wing Psychedelia: Case Studies in Cultural Plasticity and Political Pluripotency"
#45 – Part Two: Digital Capitalism on Psychedelics with Emma Stamm
In part two of our conversation with Villanova visiting professor of philosophy Emma Stamm, we discuss the "psychedelic industry's" increasing fixation on digital capitalism. Looking at apps like MyDelica and hardware like Kernel's brain-scanning helmet, we discuss how the social implications of this technology extend well beyond psychedelia.
Join Our Newsletter
Independent reporting. Critical analysis. In your inbox.
Join Our Newsletter
Independent reporting. Critical analysis. In your inbox.
#49 – Part One: Jordan Peterson’s Psychedelic Hierarchy, ft. Thought Slime
In part 1 of this deep dive, Psymposia and Thought Slime analyze Jordan Peterson's fascination with psychedelics as an example of the reactionary, right-wing ideologies that have been developing within psychedelia in recent decades. Reacting to a 2021 podcast of Peterson's, we discuss the significance of Peterson's popularity among some prominent psychedelic researchers.
#52 – Right-Wing Psychedelia at University of Madison-Wisconsin
This presentation highlights the numerous contemporary and historical cases where the use of psychedelics failed to reduce authoritarian tendencies in users, or even facilitated adoption of authoritarian views.
#48 – Drugs and Anti-Capitalism with Hilary Agro
We talk drugs and anti-capitalism with anthropology PhD candidate, Hilary Agro. Ranging from prohibition to psychedelic clinical trials and beyond, we explore the overlaps and differences in our analyses of the current psychedelic (and broader drug policy) landscape.
Series
A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.
A six part series on the intersection of psychedelics and capitalism, and the early investors making it happen.
From Mining to Mushrooms
A series exploring the infiltration of the psychedelic pharmaceutical industry by companies, investors, and executives from extractive industry.
Corporadelic
A series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Corporadelic
A series on the intersection of psychedelics and capitalism, and the early investors making it happen.
Talking Psychedelic Capitalism in a WeWork Ballroom
Psychedelic capitalists justify their decision to go for-profit in the ballroom of America’s most recent for-profit flop.